Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 104 entries
Sorted by: Best Match Show Resources per page
Liraglutide for weight management: a critical review of the evidence.

Obesity science & practice

Mehta A, Marso SP, Neeland IJ.
PMID: 28392927
Obes Sci Pract. 2017 Mar;3(1):3-14. doi: 10.1002/osp4.84. Epub 2016 Dec 19.

OBJECTIVE: To review the efficacy, safety, and clinical applicability of liraglutide for weight management from phase III clinical trials.METHODS: A search of the English language literature was performed using PubMed search terms: "liraglutide", "glucagon-like peptide-1 receptor agonist", and "randomized...

Cite
Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2016;3(1):3-14doi: 10.1002/osp4.84.
Mehta, A., Marso, S. P., & Neeland, I. J. (2017). Liraglutide for weight management: a critical review of the evidence. Obesity science & practice, 3(1), 3-14. https://doi.org/10.1002/osp4.84
Mehta, A, et al. "Liraglutide for weight management: a critical review of the evidence." Obesity science & practice vol. 3,1 (2017): 3-14. doi: https://doi.org/10.1002/osp4.84
Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017 Mar;3(1):3-14. doi: 10.1002/osp4.84. Epub 2016 Dec 19. PMID: 28392927; PMCID: PMC5358074.
Copy Download .nbib Format: NLM
Stimulants for the Control of Hedonic Appetite.

Frontiers in pharmacology

Poulton AS, Hibbert EJ, Champion BL, Nanan RK.
PMID: 27199749
Front Pharmacol. 2016 Apr 25;7:105. doi: 10.3389/fphar.2016.00105. eCollection 2016.

The focus of this paper is treatment of obesity in relation to the management of hedonic appetite. Obesity is a complex condition which may be potentiated by excessive reward seeking in combination with executive functioning deficits that impair cognitive...

Cite
Poulton AS, Hibbert EJ, Champion BL, et al. Stimulants for the Control of Hedonic Appetite. Front Pharmacol. 2016;7:105doi: 10.3389/fphar.2016.00105.
Poulton, A. S., Hibbert, E. J., Champion, B. L., & Nanan, R. K. (2016). Stimulants for the Control of Hedonic Appetite. Frontiers in pharmacology, 7105. https://doi.org/10.3389/fphar.2016.00105
Poulton, Alison S, et al. "Stimulants for the Control of Hedonic Appetite." Frontiers in pharmacology vol. 7 (2016): 105. doi: https://doi.org/10.3389/fphar.2016.00105
Poulton AS, Hibbert EJ, Champion BL, Nanan RK. Stimulants for the Control of Hedonic Appetite. Front Pharmacol. 2016 Apr 25;7:105. doi: 10.3389/fphar.2016.00105. eCollection 2016. PMID: 27199749; PMCID: PMC4843092.
Copy Download .nbib Format: NLM
Fenfluramine-Phentermine (Fen-Phen) and Seizures: Evidence for an Association.

Epilepsy & behavior : E&B

Spencer DC, Hwang J, Morrell MJ.
PMID: 12737835
Epilepsy Behav. 2000 Dec;1(6):448-452. doi: 10.1006/ebeh.2000.0132.

Fenfluramine-phentermine combination therapy ("fen-phen") became a popular treatment for obesity in the 1990s. Although this treatment causes cardiac toxicity, use of these medications has not previously been associated with seizures. We report five cases with apparent association between use...

Cite
Spencer DC, Hwang J, Morrell MJ. Fenfluramine-Phentermine (Fen-Phen) and Seizures: Evidence for an Association. Epilepsy Behav. 2000;1(6):448-452doi: 10.1006/ebeh.2000.0132.
Spencer, D. C., Hwang, J., & Morrell, M. J. (2000). Fenfluramine-Phentermine (Fen-Phen) and Seizures: Evidence for an Association. Epilepsy & behavior : E&B, 1(6), 448-452. https://doi.org/10.1006/ebeh.2000.0132
Spencer, David C., et al. "Fenfluramine-Phentermine (Fen-Phen) and Seizures: Evidence for an Association." Epilepsy & behavior : E&B vol. 1,6 (2000): 448-452. doi: https://doi.org/10.1006/ebeh.2000.0132
Spencer DC, Hwang J, Morrell MJ. Fenfluramine-Phentermine (Fen-Phen) and Seizures: Evidence for an Association. Epilepsy Behav. 2000 Dec;1(6):448-452. doi: 10.1006/ebeh.2000.0132. PMID: 12737835.
Copy Download .nbib Format: NLM
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity.

Diabetes, metabolic syndrome and obesity : targets and therapy

Shin JH, Gadde KM.
PMID: 23630428
Diabetes Metab Syndr Obes. 2013 Apr 08;6:131-9. doi: 10.2147/DMSO.S43403. Print 2013.

Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term...

Cite
Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes. 2013;6:131-9doi: 10.2147/DMSO.S43403.
Shin, J. H., & Gadde, K. M. (2013). Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes, metabolic syndrome and obesity : targets and therapy, 6131-9. https://doi.org/10.2147/DMSO.S43403
Shin, Jin Hee, and Gadde, Kishore M. "Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 6 (2013): 131-9. doi: https://doi.org/10.2147/DMSO.S43403
Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes. 2013 Apr 08;6:131-9. doi: 10.2147/DMSO.S43403. Print 2013. PMID: 23630428; PMCID: PMC3626409.
Copy Download .nbib Format: NLM
Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue.

International journal of endocrinology

Dias S, Paredes S, Ribeiro L.
PMID: 29593789
Int J Endocrinol. 2018 Jan 17;2018:2637418. doi: 10.1155/2018/2637418. eCollection 2018.

Metabolic syndrome can be defined as a state of disturbed metabolic homeostasis characterized by visceral obesity, atherogenic dyslipidemia, arterial hypertension, and insulin resistance. The growing prevalence of metabolic syndrome will certainly contribute to the burden of cardiovascular disease. Obesity...

Cite
Dias S, Paredes S, Ribeiro L. Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue. Int J Endocrinol. 2018;2018:2637418doi: 10.1155/2018/2637418.
Dias, S., Paredes, S., & Ribeiro, L. (2018). Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue. International journal of endocrinology, 20182637418. https://doi.org/10.1155/2018/2637418
Dias, Sofia, et al. "Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue." International journal of endocrinology vol. 2018 (2018): 2637418. doi: https://doi.org/10.1155/2018/2637418
Dias S, Paredes S, Ribeiro L. Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue. Int J Endocrinol. 2018 Jan 17;2018:2637418. doi: 10.1155/2018/2637418. eCollection 2018. PMID: 29593789; PMCID: PMC5822899.
Copy Download .nbib Format: NLM
Cardiovascular effects of antiobesity drugs: are the new medicines all the same?.

International journal of obesity supplements

Cataldi M, Cignarelli A, Giallauria F, Muscogiuri G, Barrea L, Savastano S, Colao A.
PMID: 32714509
Int J Obes Suppl. 2020 Jul;10(1):14-26. doi: 10.1038/s41367-020-0015-3. Epub 2020 Jul 20.

Waiting for a definite answer from well-designed randomized prospective clinical trials, the impact of the new antiobesity drugs -liraglutide, bupropion/naltrexone, phentermine/topiramate and lorcaserin- on cardiovascular outcomes remains uncertain. What has been learned from previous experience with older medicines is...

Cite
Cataldi M, Cignarelli A, Giallauria F, et al. Cardiovascular effects of antiobesity drugs: are the new medicines all the same?. Int J Obes Suppl. 2020;10(1):14-26doi: 10.1038/s41367-020-0015-3.
Cataldi, M., Cignarelli, A., Giallauria, F., Muscogiuri, G., Barrea, L., Savastano, S., Colao, A. (2020). Cardiovascular effects of antiobesity drugs: are the new medicines all the same?. International journal of obesity supplements, 10(1), 14-26. https://doi.org/10.1038/s41367-020-0015-3
Cataldi, Mauro, et al. "Cardiovascular effects of antiobesity drugs: are the new medicines all the same?." International journal of obesity supplements vol. 10,1 (2020): 14-26. doi: https://doi.org/10.1038/s41367-020-0015-3
Cataldi M, Cignarelli A, Giallauria F, Muscogiuri G, Barrea L, Savastano S, Colao A. Cardiovascular effects of antiobesity drugs: are the new medicines all the same?. Int J Obes Suppl. 2020 Jul;10(1):14-26. doi: 10.1038/s41367-020-0015-3. Epub 2020 Jul 20. PMID: 32714509; PMCID: PMC7371629.
Copy Download .nbib Format: NLM
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review.

The world journal of men's health

Tak YJ, Lee SY.
PMID: 32202085
World J Mens Health. 2021 Apr;39(2):208-221. doi: 10.5534/wjmh.200010. Epub 2020 Mar 09.

As a chronic and relapsing disease, obesity negatively impacts the health of men to a greater extent than that of women, with a higher risk of cardiovascular disease. Since lifestyle modifications alone are often challenging and limited for the...

Cite
Tak YJ, Lee SY. Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. World J Mens Health. 2020;39(2):208-221doi: 10.5534/wjmh.200010.
Tak, Y. J., & Lee, S. Y. (2021). Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. The world journal of men's health, 39(2), 208-221. https://doi.org/10.5534/wjmh.200010
Tak, Young Jin, and Lee, Sang Yeoup. "Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review." The world journal of men's health vol. 39,2 (2021): 208-221. doi: https://doi.org/10.5534/wjmh.200010
Tak YJ, Lee SY. Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. World J Mens Health. 2021 Apr;39(2):208-221. doi: 10.5534/wjmh.200010. Epub 2020 Mar 09. PMID: 32202085; PMCID: PMC7994651.
Copy Download .nbib Format: NLM
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.

Lancet (London, England)

Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, Chen Z, Xu S, Shen Y, Ge L, Sun F, Li L, Yu J, Nong K, Zou X, Zhu S, Wang C, Zhang S, Qiao Z, Jian Z, Li Y, Zhang X, Chen K, Qu F, Wu Y, He Y, Tian H, Li S.
PMID: 34895470
Lancet. 2022 Jan 15;399(10321):259-269. doi: 10.1016/S0140-6736(21)01640-8. Epub 2021 Dec 08.

BACKGROUND: Pharmacotherapy provides an option for adults with overweight and obesity to reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for the benefits and harms of weight-lowering drugs.METHODS: This systematic review and network meta-analysis included...

Cite
Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2021;399(10321):259-269doi: 10.1016/S0140-6736(21)01640-8.
Shi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., Sun, F., Li, L., Yu, J., Nong, K., Zou, X., Zhu, S., Wang, C., Zhang, S., Qiao, Z., Jian, Z., Li, Y., Zhang, X., Chen, K., Qu, F., Wu, Y., He, Y., Tian, H., & Li, S. (2022). Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet (London, England), 399(10321), 259-269. https://doi.org/10.1016/S0140-6736(21)01640-8
Shi, Qingyang, et al. "Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials." Lancet (London, England) vol. 399,10321 (2022): 259-269. doi: https://doi.org/10.1016/S0140-6736(21)01640-8
Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, Chen Z, Xu S, Shen Y, Ge L, Sun F, Li L, Yu J, Nong K, Zou X, Zhu S, Wang C, Zhang S, Qiao Z, Jian Z, Li Y, Zhang X, Chen K, Qu F, Wu Y, He Y, Tian H, Li S. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022 Jan 15;399(10321):259-269. doi: 10.1016/S0140-6736(21)01640-8. Epub 2021 Dec 08. PMID: 34895470.
Copy Download .nbib Format: NLM
Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search.

Journal of clinical medicine

Goldman VE, Naguib MN, Vidmar AP.
PMID: 34640558
J Clin Med. 2021 Sep 30;10(19). doi: 10.3390/jcm10194540.

(1) Background: children with Prader-Willi syndrome (PWS) have high obesity rates due to hyperphagia and decreased metabolic rates. Although anti-obesity medications (AOMs) are prescribed to this population, there are no consensus guidelines on acceptability, safety, and efficacy. We present...

Cite
Goldman VE, Naguib MN, Vidmar AP. Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search. J Clin Med. 2021;10(19)doi: 10.3390/jcm10194540.
Goldman, V. E., Naguib, M. N., & Vidmar, A. P. (2021). Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search. Journal of clinical medicine, 10(19), . https://doi.org/10.3390/jcm10194540
Goldman, Victoria E, et al. "Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search." Journal of clinical medicine vol. 10,19 (2021). doi: https://doi.org/10.3390/jcm10194540
Goldman VE, Naguib MN, Vidmar AP. Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search. J Clin Med. 2021 Sep 30;10(19). doi: 10.3390/jcm10194540. PMID: 34640558; PMCID: PMC8509766.
Copy Download .nbib Format: NLM
Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience.

International journal of obesity (2005)

Calderon G, Gonzalez-Izundegui D, Shan KL, Garcia-Valencia OA, Cifuentes L, Campos A, Collazo-Clavell ML, Shah M, Hurley DL, Abu Lebdeh HS, Sharma M, Schmitz K, Clark MM, Grothe K, Mundi MS, Camilleri M, Abu Dayyeh BK, Hurtado Andrade MD, Mokadem MA, Acosta A.
PMID: 34811486
Int J Obes (Lond). 2021 Nov 22; doi: 10.1038/s41366-021-01019-6. Epub 2021 Nov 22.

BACKGROUND AND AIMS: Randomized clinical trials have proven the efficacy and safety of Food and Drug Administration (FDA) approved anti-obesity medications (AOMs) for long-term use. It is unclear whether these outcomes can be replicated in real-world clinical practice where...

Cite
Calderon G, Gonzalez-Izundegui D, Shan KL, et al. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. Int J Obes (Lond). 2021;doi: 10.1038/s41366-021-01019-6.
Calderon, G., Gonzalez-Izundegui, D., Shan, K. L., Garcia-Valencia, O. A., Cifuentes, L., Campos, A., Collazo-Clavell, M. L., Shah, M., Hurley, D. L., Abu Lebdeh, H. S., Sharma, M., Schmitz, K., Clark, M. M., Grothe, K., Mundi, M. S., Camilleri, M., Abu Dayyeh, B. K., Hurtado Andrade, M. D., Mokadem, M. A., & Acosta, A. (2021). Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. International journal of obesity (2005), . https://doi.org/10.1038/s41366-021-01019-6
Calderon, Gerardo, et al. "Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience." International journal of obesity (2005) vol. (2021). doi: https://doi.org/10.1038/s41366-021-01019-6
Calderon G, Gonzalez-Izundegui D, Shan KL, Garcia-Valencia OA, Cifuentes L, Campos A, Collazo-Clavell ML, Shah M, Hurley DL, Abu Lebdeh HS, Sharma M, Schmitz K, Clark MM, Grothe K, Mundi MS, Camilleri M, Abu Dayyeh BK, Hurtado Andrade MD, Mokadem MA, Acosta A. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. Int J Obes (Lond). 2021 Nov 22; doi: 10.1038/s41366-021-01019-6. Epub 2021 Nov 22. PMID: 34811486.
Copy Download .nbib Format: NLM
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.

Metabolism: clinical and experimental

Polyzos SA, Kountouras J, Mantzoros CS.
PMID: 30502373
Metabolism. 2019 Mar;92:82-97. doi: 10.1016/j.metabol.2018.11.014. Epub 2018 Nov 29.

The obesity epidemic is closely associated with the rising prevalence and severity of nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple steatosis (SS), but also with advanced disease, i.e., nonalcoholic steatohepatitis (NASH), NASH-related cirrhosis...

Cite
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2018;92:82-97doi: 10.1016/j.metabol.2018.11.014.
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019). Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism: clinical and experimental, 9282-97. https://doi.org/10.1016/j.metabol.2018.11.014
Polyzos, Stergios A, et al. "Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics." Metabolism: clinical and experimental vol. 92 (2019): 82-97. doi: https://doi.org/10.1016/j.metabol.2018.11.014
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019 Mar;92:82-97. doi: 10.1016/j.metabol.2018.11.014. Epub 2018 Nov 29. PMID: 30502373.
Copy Download .nbib Format: NLM
The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity.

Obesity science & practice

Lee M, Lauren BN, Zhan T, Choi J, Klebanoff M, Abu Dayyeh B, Taveras EM, Corey K, Kaplan L, Hur C.
PMID: 32313674
Obes Sci Pract. 2019 Dec 10;6(2):162-170. doi: 10.1002/osp4.390. eCollection 2020 Apr.

BACKGROUND: The Food and Drug Administration has approved several pharmacotherapies for the treatment of obesity. This study assesses the cost-effectiveness of six pharmacotherapies and lifestyle intervention for people with mild obesity (body mass indices [BMIs] 30 to 35).METHODS: A...

Cite
Lee M, Lauren BN, Zhan T, et al. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract. 2019;6(2):162-170doi: 10.1002/osp4.390.
Lee, M., Lauren, B. N., Zhan, T., Choi, J., Klebanoff, M., Abu Dayyeh, B., Taveras, E. M., Corey, K., Kaplan, L., & Hur, C. (2020). The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obesity science & practice, 6(2), 162-170. https://doi.org/10.1002/osp4.390
Lee, Minyi, et al. "The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity." Obesity science & practice vol. 6,2 (2020): 162-170. doi: https://doi.org/10.1002/osp4.390
Lee M, Lauren BN, Zhan T, Choi J, Klebanoff M, Abu Dayyeh B, Taveras EM, Corey K, Kaplan L, Hur C. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract. 2019 Dec 10;6(2):162-170. doi: 10.1002/osp4.390. eCollection 2020 Apr. PMID: 32313674; PMCID: PMC7156872.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 104 entries